Biomarkers of Cisplatin Resistance in Urothelial Bladder Cancer: HMGA2 and Survivin

被引：0
|
作者：
Reis, Henning [1 ]
Krafft, Ulrich [1 ]
Tschirdewahn, Stephan [1 ]
Hess, Jochen [1 ]
Harke, Nina [1 ]
Hadaschik, Boris [2 ]
Krege, Susanne [3 ]
Nyirady, Peter [4 ]
Szendroi, Attila [4 ]
Szucs, Miklos [4 ]
Modos, Orsolya [5 ]
Szekely, Eszter [6 ]
Szarvas, Tibor [1 ,4 ]
Szarvas, Tibor [1 ,4 ]
机构：
[1] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[2] Univ Duisburg Essen, Univ Hosp Essen, Essen, Germany
[3] Kliniken Essen Mitte, Essen, Germany
[4] Semmelweis Univ, Budapest, Hungary
[5] Semmelweis Univ, Clin Urol, Budapest, BP, Hungary
[6] Semmelweis Univ, Univ Hosp Budapest, Budapest, Hungary
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
938
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Biomarkers of Cisplatin Resistance in Urothelial Bladder Cancer: HMGA2 and Survivin
    Reis, Henning
    Krafft, Ulrich
    Tschirdewahn, Stephan
    Hess, Jochen
    Harke, Nina
    Hadaschik, Boris
    Krege, Susanne
    Nyirady, Peter
    Szendroi, Attila
    Szucs, Miklos
    Modos, Orsolya
    Szekely, Eszter
    Szarvas, Tibor
    Szarvas, Tibor
    MODERN PATHOLOGY, 2019, 32
  • [2] Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer
    Krafft, Ulrich
    Tschirdewahn, Stephan
    Hess, Jochen
    Harke, Nina N.
    Hadaschik, Boris
    Olah, Csilla
    Krege, Susanne
    Nyirady, Peter
    Szendroi, Attila
    Szucs, Miklos
    Modos, Orsolya
    Szekely, Eszter
    Reis, Henning
    Szarvas, Tibor
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (11) : 810.e7 - 810.e15
  • [3] Overexpression of HMGA2 in bladder cancer and its association with clinicopathologic features and prognosis HMGA2 as a prognostic marker of bladder cancer
    Yang, G. L.
    Zhang, L. H.
    Bo, J. J.
    Hou, K. L.
    Cai, X.
    Chen, Y. Y.
    Li, H.
    Liu, D. M.
    Huang, Y. R.
    EJSO, 2011, 37 (03): : 265 - 271
  • [4] CSNK2A1-mediated phosphorylation of HMGA2 modulates cisplatin resistance in cervical cancer
    Shi, Zhan
    Wu, Ding
    Xu, Hao
    Yang, Ju
    Sun, Xiaoqing
    FEBS OPEN BIO, 2021, 11 (08): : 2245 - 2255
  • [5] Investigating the role of HMGA2 plasma level as a diagnostic marker in bladder urothelial carcinoma patients
    Farah Khazem
    Almoutassem Billah Zetoune
    Journal of Cancer Research and Clinical Oncology, 151 (4)
  • [6] Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance
    Shin-Heng Chiou
    Madeleine Dorsch
    Eva Kusch
    Santiago Naranjo
    Margaret M. Kozak
    Albert C. Koong
    Monte M. Winslow
    Barbara M. Grüner
    Scientific Reports, 8
  • [7] Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance
    Chiou, Shin-Heng
    Dorsch, Madeleine
    Kusch, Eva
    Naranjo, Santiago
    Kozak, Margaret M.
    Koong, Albert C.
    Winslow, Monte M.
    Gruener, Barbara M.
    SCIENTIFIC REPORTS, 2018, 8
  • [8] HCP5 contributes to cisplatin resistance in gastric cancer through miR-128/HMGA2 axis
    Liang, Liqun
    Kang, Hongchun
    Jia, Junmei
    CELL CYCLE, 2021, 20 (11) : 1080 - 1090
  • [9] Mechanisms of cancer stem cells drug resistance and the pivotal role of HMGA2
    Huldani, Huldani
    Jasim, Saade Abdalkareem
    Sergeenva, Klunko Nataliya
    Bokov, Dmitry Olegovich
    Abdelbasset, Walid Kamal
    Turakulov, Rustam
    Al-Gazally, Moaed E.
    Ahmadzadeh, Behnam
    Jawhar, Zanko Hassan
    Siahmansouri, Homayoon
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 234
  • [10] HMGA2 as a Critical Regulator in Cancer Development
    Mansoori, Behzad
    Mohammadi, Ali
    Ditzel, Henrik J.
    Duijf, Pascal H. G.
    Khaze, Vahid
    Gjerstorff, Morten F.
    Baradaran, Behzad
    GENES, 2021, 12 (02) : 1 - 23
12345